Evidence map›Paper›PMID 30465041›Full record

ArticleJAMA network open2018

Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer.

Florian R Schroeck, Kristine E Lynch, Ji Won Chang, Todd A MacKenzie, John D Seigne, Douglas J Robertson, Philip P Goodney, Brenda Sirovich

Abstract read
In one paragraph

Article in JAMA network open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. PathologyBERT - Pre-trained Vs. A New Transformer Language Model for Pathology Domain.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Florian R SchroeckNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
Kristine E LynchNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
Ji Won ChangNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
Todd A MacKenzieNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
John D SeigneNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
Douglas J RobertsonNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
Philip P GoodneyNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).
Brenda SirovichNorris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, MacKenzie, Seigne); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire (Schroeck, MacKenzie, Robertson, Goodney, Sirovich); Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (Schroeck, Seigne); White River Junction VA Medical Center, White River Junction, Vermont (Schroeck, Robertson, Goodney, Sirovich); VA Salt Lake City Health Care System, Salt Lake City, Utah (Lynch, Chang); University of Utah, Salt Lake City (Lynch, Chang).

Funding

Creating National Surveillance Infrastructure for Priority Medical DevicesU01FD005478 · FDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI SEDRAKYAN, ART · 2015 to 2019
$6.5M
Alignment of Treatment Preferences and Repair Type for Veterans with AAAI01HX001880 · VA · WHITE RIVER JUNCTION VA MEDICAL CENTER · PI GOODNEY, PHILIP P · 2018 to 2020
–
FDA HHS U01 FD005478HSRD VA I01 HX001880
6 · The paper itself

Abstract

importanceCancer care guidelines recommend aligning surveillance frequency with underlying cancer risk, ie, more frequent surveillance for patients at high vs low risk of cancer recurrence.

objectiveTo assess the extent to which such risk-aligned surveillance is practiced within US Department of Veterans Affairs facilities by classifying surveillance patterns for low- vs high-risk patients with early-stage bladder cancer. DESIGN SETTING AND

participantsUS national retrospective cohort study of a population-based sample of patients diagnosed with low-risk or high-risk early-stage bladder between January 1, 2005, and December 31, 2011, with follow-up through December 31, 2014. Analyses were performed March 2017 to April 2018. The study included all Veterans Affairs facilities (n = 85) where both low-and high-risk patients were treated. EXPOSURES: Low-risk vs high-risk cancer status, based on definitions from the European Association of Urology risk stratification guidelines and on data extracted from diagnostic pathology reports via validated natural language processing algorithms. MAIN OUTCOMES AND MEASURES: Adjusted cystoscopy frequency for low-risk and high-risk patients for each facility, estimated using multilevel modeling.

resultsThe study included 1278 low-risk and 2115 high-risk patients (median [interquartile range] age, 77 [71-82] years; 99% [3368 of 3393] male). Across facilities, the adjusted frequency of surveillance cystoscopy ranged from 3.7 to 6.2 (mean, 4.8) procedures over 2 years per patient for low-risk patients and from 4.6 to 6.0 (mean, 5.4) procedures over 2 years per patient for high-risk patients. In 70 of 85 facilities, surveillance was performed at a comparable frequency for low- and high-risk patients, differing by less than 1 cystoscopy over 2 years. Surveillance frequency among high-risk patients statistically significantly exceeded surveillance among low-risk patients at only 4 facilities. Across all facilities, surveillance frequencies for low- vs high-risk patients were moderately strongly correlated ( CONCLUSIONS AND RELEVANCE: Patients with early-stage bladder cancer undergo cystoscopic surveillance at comparable frequencies regardless of risk. This finding highlights the need to understand barriers to risk-aligned surveillance with the goal of making it easier for clinicians to deliver it in routine practice.

Identifiers

PMID30465041
PMCPMC6241521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.